PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

NEXT STORY
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
PREV STORY
Teleflex Earns Top Spot in MedReps Best Places to Work 2022 Ranking
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cellectis Completes Sale of $47 million through its ATM program

author_avatar
NASDAQ Market News

Global Capnography Devices Market to Generate $490.9 Million Revenue By 2025: P&S Intelligence

author_avatar
NASDAQ Market News

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

author_avatar
NASDAQ Market News